Updates in NSCLC with Emphasis on Front Line Therapy

Suresh S. Ramalingam, MD explains Non-small Cell Lung Cancer (NSCLC), and identifies therapy for patients with driver mutations such as EGFR, ALK, and RET. Dr. Ramalingam also presents immunotherapy options for patients without driver mutations, and discusses new emerging therapies. 

Back to Symposium Page »


February 20, 2021

Created by

Scripps CME Connection

Related Presenters

Suresh Ramalingam, MD

Suresh Ramalingam, MD

Professor of Hematology and Medical Oncology, Roberto C. Goizueta Chair for Cancer Research Director, Division of Medical Oncology; Deputy Director, Winship Cancer Institute
Emory Winship Cancer Institute

Dr. Suresh Ramalingam is nationally recognized as an investigator and a physician in the area of small cell and non-small cell lung cancer.

View full profile